Futu News reported on December 22 that $HANXBIO-B (03378.HK)$ The grey market price has surged 25%, reaching HKD 40. With 100 shares per lot, excluding handling fees, a profit of HKD 800 can be made per lot.
Source of market data: Futu Securities
Company Overview
Hengshi Aite is a biotechnology company with proprietary expertise and experience in structural biology, translational medicine, and clinical development. Since 2016, the company has developed a product pipeline comprising one core product and nine other pipeline candidates: (i) three clinical-stage drug candidates targeting oncology, including its core product HX009 and key products HX301 and HX044; and (ii) seven preclinical-stage candidates, including antibody-drug conjugates, bispecific antibodies, and monoclonal antibodies for autoimmune and oncology markets.
Financial Overview
In terms of financial performance, Hengshi Aite has not generated revenue. To expand business operations, the majority of its funding has been allocated to research and development costs, other expenses, administrative expenses, and interest expenses. For the fiscal years 2023 and 2024, as well as the first eight months of 2025, the respective R&D expenditures were RMB 46.663 million, RMB 74.721 million, and RMB 56.178 million, accounting for 73.0%, 61.8%, and 67.2% of total operating expenses during those periods, respectively.
Futu's dark pool platform is reliable and does not crash, supporting market orders for rapid execution. Over 850,000 people use Futu to subscribe to new stock offerings, gaining an edge in the dark pool, with faster buying and selling capabilities.Come and experience it now >>
Editor/Jamie